Molecular Imaging for Response Assessment of Neuroendocrine Tumors (NET)

Area of Science:

• Oncology
• Radiology
• Nuclear Medicine

Background:

• Assessing treatment response in neuroendocrine tumors (NET) is difficult due to indolent growth, heterogeneity, and disease stabilization.
• Conventional imaging criteria have limitations for evaluating NET treatment efficacy.
• Molecular imaging, particularly somatostatin receptor (SST) PET/CT, enhances lesion detection but lacks standardized response criteria.

Purpose of the Study:

• To review current challenges in assessing NET treatment response.
• To evaluate the strengths and limitations of existing imaging modalities for NET.
• To discuss emerging strategies and future directions for optimizing therapeutic monitoring in NET.

Main Methods:

• Review of current literature on NET treatment response assessment.
• Analysis of conventional and molecular imaging techniques.
• Discussion of novel response evaluation criteria and their validation status.

Main Results:

• Standardized criteria for molecular imaging in NET are lacking, limiting its clinical utility.
• Emerging strategies like revised dimensional thresholds, density, and functional tumor volumes show potential.
• Further validation is required for routine clinical implementation of new response evaluation methods.

Conclusions:

• Optimizing therapeutic monitoring in NET requires addressing current assessment challenges.
• Molecular imaging offers advantages but needs standardized criteria for widespread adoption.
• Future research should focus on validating novel imaging-based response criteria for NET.